Chemical Nameflorbetapir F 18
Dosage FormInjection (intravenous; 500-1900 MBq/mL)
Drug ClassRadioactive diagnostic agents
CompanyEli Lilly and Company
Approval Year2012


  • Indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline.
Last updated on 7/27/2022

More on this drug: Clinical Trials

Document TitleYearSource
Amyvid (florbetapir F 18) Prescribing Information.2019Lilly USA, Indianapolis, IN
Document TitleYearSource
SNMMI procedure standard-EANM practice guideline for amyloid PET imaging of the brain. 2016The Society of Nuclear Medicine and Molecular Imaging

Have we missed a study, or would you like to comment on a study?